Crossmark

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with <scp>PARP</scp> inhibitors

Crossref DOI link: https://doi.org/10.15252/emmm.201911217

Published Online: 2020-05-13

Published Print: 2020-06-08

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Lahiguera, Álvaro

Hyroššová, Petra

Figueras, Agnès

Garzón, Diana

Moreno, Roger

Soto‐Cerrato, Vanessa

McNeish, Iain

Serra, Violeta https://orcid.org/0000-0001-6620-1065
Lazaro, Conxi

Barretina, Pilar

Brunet, Joan

Menéndez, Javier

Matias‐Guiu, Xavier

Vidal, August

Villanueva, Alberto

Taylor‐Harding, Barbie

Tanaka, Hisashi

Orsulic, Sandra

Junza, Alexandra

Yanes, Oscar

Muñoz‐Pinedo, Cristina

Palomero, Luís

Pujana, Miquel Àngel

Perales, José Carlos

Viñals, Francesc https://orcid.org/0000-0002-9918-6751
Funding

Funding for this research was provided by:

Ministerio de Economía, Industria y Competitividad, Gobierno de España (SAF2017-85869-R)

Ministerio de Economía, Industria y Competitividad, Gobierno de España (BFU2015-66030)

Instituto de Salud Carlos III (FIS PI15/00854)

Instituto de Salud Carlos III (FIS PI16/01898)

Generalitat de Catalunya (2017SGR449)
License Information

Version of Record valid from 2020-05-13
More Information

Publication History

Received: 2019-07-26

Accepted: 2020-04-09

Published: 2020-05-13